MedLife launches the EarlyCDT® test, which allows early detection of lung cancer by identifying specific autoantibodies, available in all its units.
Delia Niculescu
Current Affairs
foto:shutterstock
Always see our news on Google
MedLife Group, the leading private healthcare provider in Romania, has introduced the EarlyCDT® test, a blood-based immunologic test for the early detection of lung cancer. It identifies autoantibodies produced by the body up to 4 years before visible lesions appear. The test is non-invasive and is mainly targeted at people with risk factors, with a turnaround time of about 15 days. Studies show that the use of this test reduces late-stage diagnoses by 36%, increasing the chances of survival. MedLife reaffirms its commitment to innovation in laboratory medicine.
Sources
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Inovație în medicina de laborator: MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Latest News
09:36
Washington Post Report: Benjamin Netanyahu refused to transfer Iron Dome missile systems to Ukraine
09:08
The European regulation on AI enters a new stage: mandatory transparency and the prohibition of manipulation systems
08:57
The Interior Ministers of the European Union will meet on Tuesday to address the crisis in Ceuta.
08:32
Israeli attacks in Gaza have led to the death of at least eight people, despite the ceasefire agreement.
08:18
Colombian President Gustavo Petro has called for the prevention of an American invasion in Cuba. He proposed a dialogue with Donald Trump.
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
